Work

A phase I, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.3023

Authors: Ahmad Awada, Christian D. Rolfo, Sylvie Rottey, Laure Ysebrant de Lendonck, Wilfried A. Schroyens, Fritz Offner, Karen Silence, Torsten Dreier, Mahan Moshir, Hans de Haard, Marc Peeters, Dominique Bron, Alain Thibault, Philippe G. Aftimos

Institutions: Institut Jules Bordet, Antwerp University Hospital, Ghent University Hospital, Argenx (Belgium)

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2346375348

Cites:

Cited by: 13

Related to: 10